Financials · QUIT

Achieve Life Sciences Inc. (QUIT) financials

For the twelve months ended Sep 30, 2026, Achieve Life Sciences Inc. reported -$111.71M of net income.

Net income, TTM
-$111.71M
Cash
$59.74M
Market cap
$697.7M
Annual revenue$0
FY2018FY2019
Annual net income-$54.65M
FY2016FY2025
Annual free cash flow-$49.47M
FY2016FY2025

QUIT revenue and earnings growth

QUIT net incomeQ3 2026-$12.11M

QUIT net income was -$12.11M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$14.44M a year earlier. For the full fiscal 2025 it was -$54.65M, compared with -$39.83M in fiscal 2024.

QUIT EPSQ3 2026-$0.11

QUIT diluted EPS was -$0.11 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$1.25, compared with -$1.24 in fiscal 2024.

QUIT free cash flowQ3 2026-$8.39M

QUIT free cash flow was -$8.39M in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$49.47M.

Export CSV

Income statement

Income statement
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue------$0$0--
Research and development-$22.82M$15.81M$30.08M$23.97M$6.88M$9.67M$5.87M$3.10M$286.0K
Selling, general and admin-$16.25M$11.44M$10.72M$9.13M$7.87M$6.85M$6.95M$3.53M$1.43M
Interest expense$819.0K$2.18M$2.85M$1.79M------
Pre-tax income-$54.65M-$39.83M-$29.82M-$42.35M-$33.15M-$14.73M-$16.39M-$12.69M-$13.63M-$1.74M
Income tax---------$0
Net income-$54.65M-$39.83M-$29.82M-$42.35M-$33.15M-$14.73M-$16.39M-$12.69M-$10.58M-$1.23M
EPS, basic-$1.25-$1.24-$1.50-$4.00-$4.08-$5.42-$39.76-$72.29-$441.40-$11625.00
EPS, diluted-$1.25-$1.24-$1.50-$4.00-$4.08-$5.42-$39.76-$72.29-$441.40-$11625.00
Diluted shares43.6M32.1M19.8M10.6M8.1M2.7M412,320175,51123,972.1106.15

Balance sheet

Balance sheet
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Cash and equivalents$20.93M$12.75M$15.55M$24.77M$43.02M$35.85M$16.66M$9.52M$5.28M$15.0K
Short-term investments$15.47M$21.61M-----$5.09M-$10.23M
Receivables------$8.0K$7.0K$9.0K$478.0K
Current assets$39.89M$36.47M$16.98M$27.33M$44.59M$36.98M$17.33M$15.54M$5.91M$18.0K
Goodwill$1.03M$1.03M$1.03M$1.03M$1.03M$1.03M$1.03M$1.03M$1.03M$1.03M
Total assets$41.79M$38.63M$19.37M$29.97M$47.52M$40.30M$21.08M$19.08M$9.89M$3.81M
Current liabilities$9.08M$6.68M$20.81M$21.60M$4.55M$2.94M$2.87M$3.27M$2.01M$3.07M
Total liabilities$20.27M$17.73M$20.82M$21.67M$19.47M$3.01M$3.03M$3.28M$2.01M$3.20M
Shareholders' equity$21.52M$20.90M-$1.45M$8.30M$28.04M$37.29M$18.05M$15.80M$15.80M$610.0K

Cash flow

Cash flow
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Operating cash flow-$49.47M-$29.77M-$24.48M-$37.57M-$29.44M-$13.47M-$15.22M-$10.62M-$9.11M-$202.0K
Capital expenditures$3.0K-$21.0K--$17.0K$53.0K$46.0K-$46.0K
Free cash flow-$49.47M--$24.50M---$13.49M-$15.27M-$10.67M--$248.0K
Investing cash flow$6.11M-$21.58M-$21.0K---$17.0K$5.04M-$5.13M$12.65M$10.61M
Financing cash flow$51.53M$48.53M$15.28M$19.32M$36.61M$32.68M$17.32M$19.76M$2.00M$150.0K
Stock-based compensation$8.76M$5.33M$3.44M$3.27M$2.19M$1.29M$1.20M$854.0K$348.0K$1.65M
Depreciation and amortization$228.0K$229.0K$228.0K$236.0K$250.0K$255.0K----

Key ratios

Key ratios
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Return on equity-254.0%-190.6%--510.1%-118.2%-39.5%-90.8%-80.3%-67.0%-202.3%
Return on assets-130.8%-103.1%-153.9%-141.3%-69.8%-36.6%-77.8%-66.5%-107.0%-32.4%
Current ratio4.395.460.821.279.8012.606.044.752.930.01

Source: XBRL data Achieve Life Sciences Inc. files with the SEC, latest filing dated Nov 10, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported Nov 7, 2018; 1-for-20, first reported Aug 6, 2020.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

QUIT peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
QUIT---$111.71M-$697.7M
IDXX$4.66B+11.9%$1.18B25.4%$55.48B
ORKA---$152.57M-$7.15B
LNTH$1.56B+2.4%$269.90M17.3%$6.64B
NEOG$883.99M-0.3%-$56.10M-6.3%$2.45B
CLDX$158.0K-93.9%-$309.06M-195608.9%$2.26B
NTLA$52.89M-8.1%-$426.14M-805.7%$1.36B
QDEL$2.59B-4.5%-$369.20M-14.2%$736.9M
ACHV---$111.71M-$697.7M

QUIT FAQ

4 questions
  • Is QUIT profitable?
    No. Achieve Life Sciences Inc. reported a net loss of $111.71M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does QUIT have?
    Achieve Life Sciences Inc. reported $59.74M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • When did QUIT last report financial results?
    The latest statements here come from Achieve Life Sciences Inc.'s 10-Q filed on Nov 10, 2026, covering the period ended Sep 30, 2026.
  • Where does this QUIT financial data come from?
    Quantisnow builds these statements from the structured XBRL data Achieve Life Sciences Inc. files with the SEC. It is provided for information only and is not investment advice.